Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue jumped 4.78% since last year same period to $621.99Mn in the Q4 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 2.08% jump in its revenue since last 3-months.

Royalty Pharma Plc’s net profit jumped 2.88% since last year same period to $214.21Mn in the Q4 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -25.68% fall in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin fell -1.81% since last year same period to 34.44% in the Q4 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -27.2% fall in its net profit margins since last 3-months.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.21 - a -19.33% fall from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.21.

Royalty Pharma Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Royalty Pharma Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Royalty Pharma Plc declared 0.24 dividend per share during the earnings announcement for Q1 2026.